It is still a difficult concept for many people to grasp: how can there be harms from screening for cancer?
Maybe the study published this week in JAMA Internal Medicine, “Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer,” will make some of the potential harms a little more clear.
The analysis shows that nearly 20% of all lung cancers found by CT screening seemed to be harmless (indolent is the term the researchers used). The researchers wrote:
“These patients may undergo an invasive diagnostic procedure, have surgical resection, be given a diagnosis of lung cancer, and require multiple sequential follow-up studies when some tumors are potentially clinically insignificant. These cases of overdiagnosis are treated as any other lung cancer because it is generally not possible to distinguish indolent lesions from more aggressive tumors.”
“Putting the word ‘harmless’ next to cancer is such a foreign concept to people,” said Dr. Michael LeFevre, co-chairman of the U.S. Preventive Services Task Force.
In testimonials, patients often say lung cancer screening via CT scans cured them, but the study suggests that in many cases, “we cured them of a disease we didn’t need to find in the first place,” LeFevre said.”
WebMD quoted Dr. Otis Brawley of the American Cancer Society:
Brawley said the clinical trial had successfully detected two types of lung cancers — the 80 percent that could not be cured and the 20 percent that could be successfully treated.
“Now we’re realizing there’s a third kind of cancer — the kind that doesn’t need to be cured but can be cured,” Brawley said. “We cure some people who don’t need to be cured, but the study clearly shows by treating everyone we cure people who need to be cured.”
Meantime, the Chicago Tribune carried a story promoting a hospital’s free lung cancer screening on the same day that most other news media were reporting on the troubling findings from the study. The Tribune story made no mention of the new study. Sigh.
—————————–
Follow us on Twitter:
https://twitter.com/garyschwitzer
https://twitter.com/healthnewsrevu
It's been a big week for prostate screening news and we're not finished yet. We…
Following is a guest post from Dr. Saurabh Jha, a radiologist at the University of…
The following guest post is by Joshua Schneck, a healthcare marketer, patient advocate, journalist and…
Opinions on other issues in news, journals, PR, advertising, marketing
Not the same. One is run by a professional medical/advocacy group. Other is administered by a university-based journalism training organization. Read the journalist quotes in our piece about how this is different.
@HealthNewsRevu Isn't the Gerontological Society practice of funding fellows for coverage the same as what's used by many journalistic fellowships? See Center for Health Reporting at USC.
Comments
We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.
We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like
It's been a big week for prostate screening news and we're not finished yet. We…
Following is a guest post from Dr. Saurabh Jha, a radiologist at the University of…
The following guest post is by Joshua Schneck, a healthcare marketer, patient advocate, journalist and…